Immunosuppression by anti-interleukin-2 receptor antibody but not anti-L3T4 requires terminal complement components.
Kelley
V E
VE
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02215.
Strom
T B
TB
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D003182:Complement C5 / Q000172:deficiency; D003165:Complement System Proteins / Q000276:immunology*; D006968:Hypersensitivity, Delayed; D007165:Immunosuppression Therapy; D008213:Lymphocyte Activation; D051379:Mice; D008805:Mice, Inbred A; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D003182:Complement C5; D015375:Receptors, Interleukin-2; D003165:Complement System Proteins